Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: Results from the SYNERGY trial

European Heart Journal

Volumn 29, Issue 15, 2008, Pages 1827-1833

  Lopes, Renato D ^a   Alexander, Karen P ^a   Marcucci, Gretchen ^a   White, Harvey D ^b   Spinler, Sarah ^c   Col, Jacques ^d   Aylward, Philip E ^e   Califf, Robert M ^a   Mahaffey, Kenneth W ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Green Lane Cardiovascular Service ^*  (New Zealand)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Age; Enoxaparin; Non ST segment elevation acute coronary syndromes; Outcomes; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART DISEASE; HEPARINIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; LOGISTIC MODELS; MALE; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 48749122759     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn236     Document Type: Article

References (28)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:652-726.
2. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Foody JM, Boden WE, Smith SC Jr, Gibler WB, Ohman EM, Peterson ED CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005;46:1479-1487.
3. Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G GRACE Investigators. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2007;153:960-969.
4. Giugliano RP, Camargo CA Jr, Lloyd-Jones DM, Zagrodsky JD, Alexis JD, Eagle KA, Fuster V, O'Donnell CJ. Elderly patients receive less aggressive medical and invasive management of unstable angina: potential impact of practice guidelines. Arch Intern Med 1998;158:1113-1120.
5. Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J 2000;140:81-93.
6. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Kristensen SD, Widimsky P, McGregor K, Sechtem U, Tendera M, Hellemans I, Gomez JL, Silber S, Funck-Brentano C, Kristensen SD, Andreotti F, Benzer W, Bertrand M, Betriu A, De Caterina R, DeSutter J, Falk V, Ortiz AF, Gitt A, Hasin Y, Huber K, Kornowski R, Lopez-Sendon J, Morais J, Nordrehaug JE, Silber S, Steg PG, Thygesen K, Tubaro M, Turpie AG, Verheugt F, Windecker S ESC Committee for Practice Guidelines (CPG), Task Force for Diagnosis. Treatment of non-ST-segment elevation acute coronary syndromes of European society of cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-1660.
7. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. (Erratum Lancet 2000;356:600). Lancet 2000;355:1936-1942.
8. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2549-2569.
9. SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 2002;143:952-960.
10. Rao SV, Mahaffey KW, Antman E, Kleiman NS, Ferguson JJ, Califf RM, Becker RC, Goodman SG, Aylward PE. Predictors of major bleeding and transfusion in SYNERGY: effects of pretreatment variables and treatment assignment. (Abstract 850-855). J Am Coll Cardiol 2005;45(Suppl. A):247A.
11. Mahaffey KW, Pieper KS, Antman E, Goodman SG, Cohen M, Aylward PE, Col JJ, Ferguson JJ on behalf of the SYNERGY Trial Investigators. Predictors of one-year mortality in high-risk patients with acute coronary syndromes: the SYNERGY trial one-year results. (Abstract 1916). Eur Heart J 2006;27(Suppl. 1):305.
12. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-2567.
13. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
14. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
15. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64.
16. Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr CRUSADE Investigators. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. J Thromb Thrombolysis 2006;21:211-220.
17. Antman EA, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the TIMI 11B trial. Circulation 1999;100:1593-1601.
18. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). (Erratum Circulation 1998;97:413). Circulation 1997;96:61-68.
19. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-1562.
20. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96.
21. Zeymer U, Gitt A, Junger C, Koeth O, Zahn R, Wienbergen H, Gottwik M, Senges J ACOS-Registry Participants. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. Am J Cardiol 2006;98:19-22.
22. Gore JM, Spencer FA, Goldberg RJ, Kennelly BM, Fox KA, Allegrone J, Eagle KA, Anderson FA Jr, Steg PG GRACE Investigators. Use of heparins in non-ST-elevation acute coronary syndromes. Am J Med 2007;120:63- 71.
23. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, Eagle KA, White K, Mehta RH, Knobel E, Collet JP GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005;149:67-73.
24. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ III, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042- 1050.
25. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E A to Z Investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 2004;25:1688-1694.
26. LaPointe NM, Chen AY, Alexander KP, Roe MT, Pollack CV Jr, Lytle BL, Ohman ME, Gibler WB, Peterson ED. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non-ST-segment elevation acute coronary syndromes. Arch Intern Med 2007;167:1539-1544.
27. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-3116.
28. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, Antman EM. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart 2007;28:1066-1071.